Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Find information and resources for current and returning patients.
Learn about clinical trials at MD Anderson and search our database for open studies.
The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.
Your gift will help support our mission to end cancer and make a difference in the lives of our patients.
Our personalized portal helps you refer your patients and communicate with their MD Anderson care team.
As part of our mission to eliminate cancer, MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.
Choose from 12 allied health programs at School of Health Professions.
Learn about our graduate medical education residency and fellowship opportunities.
Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer.
Yamauchi, T., Espinosa Fernandez, J. R., Imamura, C. K., Yamauchi, H., Jinno, H., Takahashi, M., et al
JAMA Oncology, 2017
Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review.
Torres-Adorno, A. M., Lee, J., Kogawa, T., Ordentlich, P., Tripathy, D., Lim, B., & Ueno, N. T
Clinical Cancer Research, 2017
Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer
Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer.
T. Fujii, T. Kogawa, W. Dong, A. A. Sahin, S. Moulder, J. K. Litton, D. Tripathy, T. Iwamoto, K. K. Hunt, L. Pusztai et al
c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun
Xie, X., Kaoud, T. S., Edupuganti, R., Zhang, T., Kogawa, T., Zhao, Y., et al
The Lancet Oncology, 2017
Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system
Fouad, T. M., Barrera, A. M. G., Reuben, J. M., Lucci, A., Woodward, W. A., Stauder, M. C., et al
Molecular Cancer Therapeutics, 2015
MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model
Bartholomeusz, C., Xie, X., Pitner, M. K., Kondo, K., Dadbin, A., Lee, J., et al
JAMA Oncology, 2015
Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis
Fujii, T., Le Du, F., Xiao, L., Kogawa, T., Barcenas, C. H., Alvarez, R. H., et al
PLoS One, 2017
Androgen receptor expression on circulating tumor cells in metastatic breast cancer
Fujii, T., Reuben, J. M., Huo, L., Espinosa Fernandez, J. R., Gong, Y., Krupa, R., et al
Somatic mutations reveal asymmetric cellular dynamics in the early human embryo
Ju, Y. S., Martincorena, I., Gerstung, M., Petljak, M., Alexandrov, L. B., Rahbari, R., et al
Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
Kai, K., Kondo, K., Wang, X., Xie, X., Pitner, M. K., Reyes, M. E., et al
Breast Cancer Research and Treatment, 2017
Identification of frequent somatic mutations in inflammatory breast cancer
Matsuda, N., Lim, B., Wang, Y., Krishnamurthy, S., Woodward, W., Alvarez, R. H., et al